HOME >> BIOLOGY >> NEWS
Brain neurochemicals, not gender, tell a female to act like a female

ITHACA, N.Y. -- Cornell University biologists have shown how chemicals produced in a core region of the brain shared by all vertebrate animals (including humans) make males act like males, females like females -- and some males something like females.

James Goodson and Andrew Bass, who studied a fish species that produces two types of males for their report in the Feb. 17, 2000, issue of the journal Nature, say that brain processes responsible for social behavior typical of females, for example, aren't necessarily linked to the female's sex at all.

"This is a clear demonstration of how the action of neurochemicals can modulate the electrical or neurophysiological output of the brain as it establishes a social behavior," said Bass, professor of neurobiology and behavior, in an interview.

"We have also shown that there can be a neurochemical dissociation -- an uncoupling -- between an animal's gonadal sex and the regulation of behaviors typical of a sex," said Goodson, a postdoctoral fellow in Bass' neurobiology laboratory.

The part of the brain studied by Goodson and Bass is the preoptic area-anterior hypothalamus, a section of the basal forebrain, which neurobiologists say has been "conserved" throughout the evolution of vertebrates. The functions and structure of this conserved brain region are strikingly similar in fish, amphibians, reptiles, birds and mammals, including humans. The neurochemicals credited with sex-related social behaviors are isotocin and vasotocin in fish and are essentially the equivalents of oxytocin and vasopressin, respectively, in mammals.

The fish that made the neurochemical finding possible is the plainfin midshipman (Porichthys notatus), best known for its singing in shallow salt water at mating time. Most of the noise comes from male midshipman fish of the type I variety, which vocalize for hours under rocks to attract females. When type I males' courtship songs are successful, female
'"/>

Contact: Roger Segelken
hrs2@cornell.edu
607-255-9736
Cornell University News Service
15-Feb-2000


Page: 1 2 3 4

Related biology news :

1. Brain has center for detecting sound motion
2. Brains reward circuitry revealed in procrastinating primates
3. Brain serotonin enzyme finding might explain psychiatric disorders
4. Brain development and puberty may be key factors in learning disorders
5. Organization for Human Brain Mapping 2004 Annual Meeting
6. Brain disease research, particle physics meet in the middle (ware)
7. Brain control
8. Brain cells become more discriminating when they work together
9. Brain signal predicts working memory prowess
10. Brain areas identified that decode emotions of others
11. Brain Centre gives Wales a world lead

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Brain neurochemicals not gender tell female act like female

(Date:4/10/2015)... Research and Markets ( http://www.researchandmarkets.com/research/cjk4gb/security ... Competitive Profiles - NEC" report to their offering. ... will continue to supply a range of IT security ... company focus on the development of a Big Data ... in the Asia-Pacific region is ...
(Date:4/8/2015)... , April 8, 2015  Infinisource, a ... and services, and Morpho, a leading supplier of ... to produce the market,s most advanced biometrically-enabled time ... iSolved NXG time clock is setting a bold, ... labor data for the small and mid-size employer. ...
(Date:4/2/2015)... 2, 2015 In the ... far outperforms the strongest competitors, showing outstanding performance ... the system is capable of a throughput of ... up to be ten times faster than most ... performance.      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
(Date:4/16/2015)... (PRWEB) April 16, 2015 Regis Technologies ... American Association for Cancer Research (AACR) annual meeting. Regis ... Convention Center, starting Saturday, April 18, in Philadelphia and ... claim to title of the oldest and largest organization ... fellowships and grants, and partners with survivors to promote ...
(Date:4/16/2015)... (PRWEB) April 16, 2015 ... at Charlotte (UNC Charlotte) spin-out company, announced today ... Cooper, Ph.D., M.D., as Chief Operating Officer (COO). ... of experience in developing clinical diagnostic and biotechnology ... infectious disease. , Cooper’s extensive career transcends the ...
(Date:4/16/2015)... 16, 2015  In recognition of World Hemophilia Day, ... groups to illuminate more than 15 prominent landmarks red throughout ... Boston,s Zakim Bridge and Prudential Tower, ... Mercedes-Benz Superdome and Denver,s ... of April 17, and coincide with hemophilia community events in ...
(Date:4/16/2015)... April 16, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: ... U.S. joint venture with G-treeBNT (ReGenTree LLC) has ... clinical trial for the orphan disorder, neurotrophic keratopathy ... dry eye syndrome (DES) in the U.S.  Both ... RGN-259/GBT201, this year.  Each of these eye disorders ...
Breaking Biology Technology:Regis Technologies Joins American Association for Cancer Research Annual Meeting 2OncoTAb Names Dr. David L. Cooper as COO 2Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 2Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 3Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5
Cached News: